 |
|
|
| |
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5 or 6 Infection:
Final Results of the ENDURANCE-5,6 Study
|
| |
| |
Reported by Jules Levin
The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2018, San Francisco, California, United States
Samuel S Lee1, Tarik Asselah2, Bett y Yao3, Tuan Nguyen4, Florence Wong5, Adam Mahomed6, Seng Gee Lim7, Armand Abergel8, Joe Sasadeusz9, Edward Gane10, Kati a Alves3*, Preethi Krishnan3, Zhenzhen Zhang3, Ariel Porcalla3, Federico J Mensa3, Kinh Nguyen11
1University of Calgary, Calgary, Alberta, Canada; 2Centre de Recherche sur l'Infl ammati on, INSERM UMR 1149, Université Paris Diderot, Department of Hepatology, AP-HP Hôpital Beaujon, Clichy, France; 3AbbVie Inc., North Chicago, Illinois, United States; 4Research and Educati on, Inc., San Diego, California, United States; 5Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada; 6Faculty of Health Sciences, University of Witwatersrand, Charlott e Maxeke Johannesburg Academic Hospital, Department of Gastroenterology and Hepatology, South Africa; 7Division of Gastroenterology and Hepatology, Nati onal University Health System, Singapore; 8CHU Estaing, Clermont Ferrand, France; 9Royal Melbourne Hospital, Melbourne, Victoria, Australia; 10Auckland Clinical Studies, Auckland, New Zealand; 11Nati onal Hospital for Tropical Diseases, Vietnam
*Former employee of AbbVie; employee of AbbVie during the study
|
| |
|
|
|
|
|
